ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Galecto Inc

Galecto Inc (GLTO)

6.355
-0.565
(-8.16%)
Closed November 18 4:00PM
6.355
0.00
(0.00%)
After Hours: 4:00PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
6.355
Bid
6.11
Ask
9.50
Volume
8,448
6.355 Day's Range 6.76
6.355 52 Week Range 23.50
Market Cap
Previous Close
6.92
Open
6.76
Last Trade
3
@
6.44
Last Trade Time
Financial Volume
$ 55,431
VWAP
6.5615
Average Volume (3m)
165,037
Shares Outstanding
1,316,989
Dividend Yield
-
PE Ratio
-0.22
Earnings Per Share (EPS)
-29.12
Revenue
-
Net Profit
-38.35M

About Galecto Inc

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitor... Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Galecto Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GLTO. The last closing price for Galecto was $6.92. Over the last year, Galecto shares have traded in a share price range of $ 6.355 to $ 23.50.

Galecto currently has 1,316,989 shares outstanding. The market capitalization of Galecto is $9.11 million. Galecto has a price to earnings ratio (PE ratio) of -0.22.

GLTO Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.745-10.49295774657.17.16.35575417.02218353CS
4-0.585-8.429394812686.947.596.355163196.99503923CS
12-7.395-53.781818181813.7514.826.35516503711.87937234CS
26-10.6275-62.579125570416.9825176.35516034912.78887863CS
52-9.0325-58.700243704315.387523.56.35521512515.60161427CS
156-81.895-92.798866855588.2592.56.35519040529.38584293CS
260-387.895-98.3880786303394.25449.756.35523137975.6472265CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CEROCERo Therapeutics Holdings Inc
$ 0.2853
(52.40%)
1.17B
CYCNCyclerion Therapeutics Inc
$ 2.5306
(42.97%)
11.99M
SPPLSIMPPLE Ltd
$ 1.2503
(41.60%)
165.69M
PULMPulmatrix Inc
$ 6.5586
(39.54%)
5.37M
ZTEKZentek Ltd
$ 1.2574
(29.96%)
309.67k
TFFPTFF Pharmaceuticals Inc
$ 0.376101
(-76.49%)
9.35M
EYENEyenovia Inc
$ 0.10185
(-70.05%)
52.8M
CTXRCitius Pharmaceuticals Inc
$ 0.1974
(-39.89%)
11.26M
VVPRVivoPower International PLC
$ 0.8151
(-39.62%)
2.34M
IPWiPower Inc
$ 0.7302
(-39.15%)
1.15M
CEROCERo Therapeutics Holdings Inc
$ 0.2853
(52.40%)
1.15B
ELABElevai Labs Inc
$ 0.0211
(-19.47%)
377.69M
NVDANVIDIA Corporation
$ 141.98
(-3.26%)
244.07M
SPPLSIMPPLE Ltd
$ 1.2503
(41.60%)
164.49M
STISolidion Technology Inc
$ 0.44
(25.71%)
139.46M

GLTO Discussion

View Posts
Retire43 Retire43 1 month ago
GALT MENTIONED IN THIS ARTICLE.

https://www.zerohedge.com/news/2024-10-15/what-merck-doesnt-want-you-know-about-keytruda
πŸ‘οΈ0
Retire43 Retire43 1 month ago
Please watch this and comment your opinion

πŸ‘οΈ0
Monksdream Monksdream 2 months ago
GLTO under $15
πŸ‘οΈ0
Retire43 Retire43 5 months ago
BIXT:

https://www.globenewswire.com/news-release/2024/06/27/2905450/0/en/Bioxytran-s-Advisor-Releases-Book-on-Hyperbaric-Oxygenation-Related-to-Stroke-Alzheimer-s-Patients.html
πŸ‘οΈ0
Retire43 Retire43 6 months ago
Share this.


https://medicaldialogues.in/medicine/news/galectin-3-promising-biomarker-for-predicting-long-covid-among-patients-of-covid-19-study-129158
πŸ‘οΈ0
Retire43 Retire43 6 months ago
Share this news with everyone, you know

https://www.insiderfinancial.com/post/playing-the-bird-flu-trade-cvac-bixt-nnvc-govx-dyai-nvax
πŸ‘οΈ0
Retire43 Retire43 6 months ago
Todays emerging growth conference
CEO DAVID PLATT $BIXT
BioxyTran.

https://emerginggrowth.com/emerging-growth-conference-70/

πŸ‘οΈ0
Retire43 Retire43 7 months ago
https://www.nasdaq.com/press-release/6-stocks-positioned-to-soar-as-investors-focus-on-mash-2024-04-22
πŸ‘οΈ0
Retire43 Retire43 11 months ago
https://www.zerohedge.com/news/2023-12-12/disease-x-resistance-futile
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 1 year ago
glto on the move
πŸ‘οΈ0
subslover subslover 1 year ago
Galecto Announces Plans to Explore Strategic Alternatives
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. Galecto has made the determination to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value.

As part of this evaluation process, Galecto will explore potential strategic alternatives that may include, but are not limited to, an acquisition, merger, business combination, divestiture of its assets, technologies or capabilities, or other transaction. There can be no assurance that its exploration will result in Galecto pursuing a transaction or that any transaction, if pursued, will be completed on attractive terms, if at all.

In connection with the evaluation of strategic alternatives, Galecto plans to implement a restructuring plan that includes reducing its workforce by approximately 29 people, or approximately 70% of its existing headcount.

Galecto has not set a timetable for completion of the evaluation process and does not intend to disclose further developments or guidance on the status of its programs unless and until it is determined that further disclosure is appropriate or necessary.

As of June 30, 2023, Galecto’s cash, cash equivalents and investments balance was $52.1 million.
πŸ‘οΈ0
Retire43 Retire43 1 year ago
Please share this!

Science buff #Investor #vaccinated #unvaccinated #COVID19 #LongCovid #Covid #masks #masksdontwork we want all to hear about a new paradigm in #drug development. $BIXT @buffalofireside talk about #galectin #drugs & potent #antiviral https://t.co/vma2hIy6CY @EnemyInAState pic.twitter.com/ARIwmsS65t— Mike Sheikh (@MikeSheikh2) September 20, 2023
πŸ‘οΈ0
Retire43 Retire43 1 year ago
Look at this Reprint. Share this !

https://www.preprints.org/manuscript/202309.0077/v1
πŸ‘οΈ0
Retire43 Retire43 1 year ago
https://www.zerohedge.com/news/2023-09-12/mask-mandates-unpopular-due-existence-next-gen-antivirals-pipeline
πŸ‘οΈ0
Retire43 Retire43 1 year ago
Did anyone catch this today ?

H.C. Wainwright 25th Annual Global Investment Conference

Date: Monday, September 11, 2023
Time: 7:00 am ET
Location: New York City, NY
πŸ‘οΈ0
Butchmass Butchmass 1 year ago
When is this company going to start doing more to publicize itself. They could be more up front and active with the share holders.
πŸ‘οΈ0
Triple nickle Triple nickle 1 year ago
Added a few down here
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
Damn shame
Sold quite a while ago at a profit
πŸ‘οΈ0
TheFinalCD TheFinalCD 1 year ago
$GLTO (.80) -65% Galecto to discontinue development of lung disease treatment
Reuters
Tue, August 15, 2023 at 7:35 AM EDT

Aug 15 (Reuters) - Galecto Inc said on Tuesday it will dicontinue development of its lung disease treatment after it failed to meet its primary goal in a mid-stage study. (Reporting by Sriparna Roy in Bengaluru; Editing by Arun Koyyur)

https://finance.yahoo.com/news/galecto-discontinue-development-lung-disease-113556937.html
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
GLTO now ;No 11; on the Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
GLTO new 52/week high
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
πŸ‘οΈ0
Butchmass Butchmass 1 year ago
Monksdream, I hope we see considerable more traffic on this board soon. Earnings coming out 7/28/2023.
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
GLTO No 3 on the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock